Background. Reported sensitivity of the galactomannan enzyme immunoassay as an early diagnostic test for invasive aspergillosis (IA) has been widely variable, ranging from 29% to 100% in earlier clinical studies.
administration of preventive mold-active antifungal therapy. However, performance studies have used perpatient analyses, classifying subjects as either case patients or control patients according to outcomes during treatment courses; in such studies, clinical variables that change over time, such as receipt of prophylactic or empirical antifungal therapy and sample timing relative to infection diagnosis, are not adequately accounted for in sensitivity analyses.
In the current study, we determined performance of the assay in a large cohort of North American patients who received either cytotoxic therapy or a hematopoietic stem cell transplant (HSCT) for hematological malignancies, using per-patient and per-test calculations. Patients who underwent HSCT and were randomized to receive either itraconazole or fluconazole for antifungal prophylaxis [7] were included to assess the time-dependent impact of mold-active antifungal therapy administered during test sampling. rolled in the randomized prophylaxis trial were followed-up prospectively to evaluate clinical onset of Aspergillus infection. The clinical records of patients enrolled in the other studies were evaluated retrospectively to determine presence or absence of invasive aspergillosis (IA), date of diagnosis, date of clinical onset, and receipt of antifungal therapies. IA was defined using the criteria outlined in published definitions [8] , except that results of GM EIA testing were not considered to be part of the diagnostic criteria. Day of diagnosis of IA was considered to be the day on which results of the confirmatory test (microbiological or histopathological) were obtained. The days on which mold-active antifungal drugs were administered were also determined by chart review; drugs available during the period included itraconazole (administered orally or intravenously), intravenous amphotericin B deoxycholate, lipid formulations of amphotericin B, voriconazole, and caspofungin.
Sensitivity and specificity were calculated on both a perpatient and a per-test outcome basis. For the per-patient calculation, each patient was classified as positive if they ever had a positive test result, determined for a range of cutoff index criteria. Thus, sensitivity was calculated as the proportion of patients with a diagnosis of proven or probable Aspergillus infection who had at least 1 positive test result. Similarly, specificity was determined by the proportion of control patients who never had a positive test result. Cases that were classified as possible Aspergillus infection were not included in the analyses, because this group contains a great deal of diagnostic uncertainty. Analyses of this outcome were performed using standard methods for binomial proportions to calculate CIs. The per-test calculations were performed treating the test result as the unit of observation, thus allowing us to evaluate the impact of factors that change over time for a patient and the impact of proximity of sampling to diagnosis time. For this analysis, sensitivity was calculated as the proportion of all test results for a patient with proven or probable Aspergillus infection that were positive. Specificity was the proportion of all test results for control patients that were negative. To appropriately account for the fact that multiple test results for each patient were used, we used logistic regression models with generalized estimating equation adjustments to calculate robust variance estimates for parameter values and, subsequently, sensitivity and specificity estimates. We further evaluated the impact of shifting index cutoffs, use of antifungal therapy, and time relative to diagnosis, using these factors as covariates in such models [9] .
Time since diagnosis was incorporated using a flexible cubic spline function in the logistic regression model. Cubic splines impose few shape restrictions on the curve, thus allowing us to observe changes in sensitivity over time. Receiver operator characteristic curves were used to visually illustrate the impact of shifting the index cutoff on the trade offs between truepositive (sensitivity) and false-positive ( ) rates. 1 Ϫ specificity All reported P values are 2-sided and were considered to be significant if they were !.05.
RESULTS

Characteristics of patients.
A total of 331 patients were initially identified for evaluation; 247 patients had been followed as part of the FHCRC randomized trial, 56 patients were enrolled in the longitudinal study in Seattle, and 38 patients received care in Montreal. The data set was restricted to include only data from those patients who had cases of proven or probable IA and serum samples obtained within 14 days before or after diagnosis; the 315 patients in the data set were grouped as follows: 20 patients with proven IA, 26 patients with probable IA, and 269 control patients. Demographic and treatment characteristics of these patients are shown in table 1. Nine patients received a diagnosis of possible IA; because of diagnostic uncertainty, these patients were not included as either case patients or control patients. The low number of patients and serum samples available did not enable accurate subgroup analyses.
A total of 3841 serum samples were available from 315 patients. Three thousand and five samples were obtained from control patients (median number of tests per patient, 11; range, 1-61 tests). Case patient samples were restricted to those samples obtained within 14 days before or after diagnosis, resulting in 120 samples obtained from patients with proven IA (median number of tests per patient, 4; range, 1-22 tests) and 152 samples obtained from patients with probable IA (median number of tests per patient, 5; range, 1-20 tests).
Performance of the GM EIA: sensitivity and specificity. In per-patient calculations of sensitivity and specificity, each patient was categorized according to whether they had any positive test result during the 14-day diagnostic window. Sensitivity and specificity, calculated using different GM index cutoff values to define a positive test result, are shown in table 2. The sensitivity to detect proven or probable IA increased from 43% to 70% when the GM EIA index value to define positivity was decreased from 1.5 to 0.5 ( ). The lowering of the P p .01 index value resulted in a decrease in per-patient specificity from 93% to 70%. The duration of time between the day of the first positive test result and the day of IA diagnosis using traditional Figure 1 . Sensitivity of the galactomannan EIA, plotted as a function of time relative to diagnosis, using multiple index cutoff values for patients not receiving (A) and patients receiving (B) antifungal therapy. Positivity was defined as an assay result greater than the index cutoff value. Sensitivity was modeled using generalized estimating equation logistic regression models, allowing time to diagnosis to impact the shape flexibly with cubicspline functions.
methods increased from 1 day prior to diagnosis (range, Ϫ12 to 12 days) to 2.5 days prior to diagnosis (range, Ϫ13 to 13) when the index value was decreased from 1.5 to 0.5. Because patients were receiving mold-active antifungal therapy for differing periods during serum sampling, classifying patients as receiving or not receiving mold-active antifungal therapy for per-patient analysis is difficult. To determine the effects of antifungal therapy and temporal proximity of sample collection to diagnosis day, analyses were performed with consideration of all test results. In these analyses, we considered the length of time between specimen date and diagnosis date and considered whether a patient was receiving antifungal therapy at the time of each test result. Table 3 shows that the sensitivity of tests performed during the week of diagnosis (week 0) was highest, again with increased sensitivity using the index cutoff value of 0.5. These data also indicate that admin- NOTE. Data are percentage of samples positive for IA (95% CI), unless otherwise indicated. Weeks indicated correspond to the following range of days: week Ϫ2, day 14 through day 8 before diagnosis; week Ϫ1, day 7 through day 1 before diagnosis, week 0, day of diagnosis through day 7 after diagnosis; and week 1, day 8 through day 14 after diagnosis.
a Data includes 18 samples for which data on receipt of antifungal therapy were missing.
istration of mold-active antifungal therapy on the day of test sampling decreased the sensitivity of the assay. With use of the 0.5 index cutoff value, the sensitivity of all tests performed during week 0 for all patients was 59% (95% CI, 41%-75%). Among samples obtained during days of antifungal therapy in the same period, the sensitivity was 52% (95% CI, 32%-71%); among samples obtained while patients were not receiving antifungal therapy in the same period, the sensitivity was significantly higher ( ) at 89% (95% CI, 65%-97%). These P p .02 data are shown in figure 1 , which demonstrates that the sensitivity is highest and the peak occurs earliest for samples obtained from patients not receiving preventive antifungal therapy.
Specificity, calculated considering the results of all 3005 tests performed on samples obtained from the 269 control patients, did not change considerably when the GM index cutoff value was decreased from 1.5 to 0.5 (table 4). In these analyses, similar specificity results were obtained for samples collected from control patients regardless of receipt of mold-active antifungal therapy.
Receiver operator characteristic curves were evaluated to demonstrate the accuracy of test results according to week of sampling and concomitant administration of mold-active antifungal therapy. Figure 2 shows that the test performed best during the week of diagnosis (week 0), with highest accuracy (greatest area) achieved in the absence of antifungal therapies. It is of note that accuracy appears to be equivalent in tests performed for patients receiving or not receiving antifungal therapy during the early diagnostic period (weeks Ϫ1 and Ϫ2; latter data not shown). Separation of the curves closer to the day of diagnosis (week 0) may represent an increased fungal burden that results from progression of infection in patients not receiving adequate mold-active antifungal therapy.
DISCUSSION
Establishing an early diagnosis of IA remains a challenge. As a result, infections may be far advanced at the time of diagnostic confirmation, and overall outcomes are poor; the most recent studies have demonstrated overall survival rates of 60%-70% at 3 months after infection [10] . For these reasons, emphasis has been placed on developing tests that will both confirm diagnosis in patients with signs and symptoms of disease and provide early clues of infection (or impending infection) when applied as a screening tool. The BioRad GM EIA is one such diagnostic test that may be applied for these purposes; however, reported diagnostic performance has been controversial. Although specificity of the test has been high (i.e., 190%) in almost all studies performed, reported sensitivities have been widely variable, ranging from 29% to 100% in the literature [3] . The present study, which represents one of the largest analyses of serum samples obtained from patients at high risk for IA, adds to our understanding of the diagnostic assay by demonstrating that the performance of the assay is variable, depending on receipt of preventive mold-active antifungal therapy. This finding likely explains some controversies in observed and reported sensitivities in the literature. Also, it has important implications for preventive and diagnostic clinical strategies.
GM is present on the surface of and is released into surrounding tissue during hyphal growth of Aspergillus species. As discussed in a recent review [3] , multiple biological factors, such as environmental growth conditions (e.g., pH and carbon source), can alter the quantity of GM released, as well as the size and number of galactofuran side-chains of the polysaccharide, thereby impacting EB-A2 antibody binding capacity. Host factors, such as receipt of antifungal therapy, are also likely to impact sensitivity of the assay; although this has been demonstrated by in vitro studies and animal models of Aspergillus infection [4] [5] [6] 11] , no prior clinical studies have definitively demonstrated the impact of antifungal administration on performance of serum-based assays.
In animal models, serum GM index values correlate with fungal burden [4] [5] [6] 11] . One study using a rabbit model of invasive pulmonary aspergillosis demonstrated that antifungal prophylaxis with posaconazole decreases circulating GM indices [11] . Two studies that evaluated the utility of the GM EIA applied to bronchoalveolar lavage fluids noted that sensitivity of the assay is decreased in patients who are already receiving antifungal therapy [12, 13] ; one study demonstrated a similar trend using quantitative PCR, suggesting that the impact of antifungals is secondary to decreased fungal burden rather than the result of direct effects on hyphal GM secretion [13] . The results of the current study demonstrate that receipt of moldactive antifungal therapy, defined as receipt of itraconazole prophylaxis and empirical mold-active antifungal therapy, decreases the sensitivity of the serum assay in per-test calculations, impairing the ability of the assay to provide an early indicator of breakthrough infection. The fact that multiple earlier clinical studies analyzed the performance of the assay for patients receiving itraconazole prophylaxis and clinically-driven empirical therapies [12, 14, 15] without explicitly accounting for these variables may account for a large amount of variability in reported sensitivities.
The results of this study illustrate several important aspects of study design and analysis. Most studies that have analyzed the performance of this diagnostic test have used per-patient analyses. The major drawback of classifying patients using this approach is that sampling frequency can bias diagnostic classification and outcomes; patients that have many samples tested have a higher chance of meeting the definition for positivity than patients with fewer tests sampled during the same period. These analyses cannot adequately account for clinical variables that change over time, such as receipt of prophylactic or empirical antifungal therapy and sample timing relative to infection diagnosis.
The finding that preventive antifungal therapies affect diagnostic performance has a direct impact on the way that we approach this disease. Currently, antifungals are frequently administered preventively (as prophylaxis in patients at high risk for fungal infection) and for fever during neutropenia. We found that circulating GM indices are not as high in patients receiving these therapies as they are in patients receiving fluconazole, which suggests that the overall fungal burden may be decreased with the preventive approach. Future studies evaluating the performance of the GM EIA will need to consider variability introduced by administration of mold-active antifungal drugs. This will also need to be considered in trials evaluating preventive therapies, because this surrogate marker is often included in the definition of infection.
In our analyses, the receipt of all mold-active antifungals was generalized, instead of considering the effects of different antifungal drugs, largely because of the limited number of data points in separate subgroups. However, different antifungal drugs may impact circulating GM levels differently. For example, it was previously suggested that echinocandin antifungals may paradoxically increase GM levels by inducing hyphal fragmentation [16] . More studies will need to be done to determine the precise impact of different antifungal drugs administered for preventive purposes. Such studies would need to consider both the dose of the drug(s) and the duration of exposure.
The results of this study confirm that the GM EIA is most sensitive when a low index cutoff value is used to define positivity. Results of multiple recent studies suggest that the index cutoff value to define positivity should be !1.0, with studies alternatively showing optimized performance at indices from 0.5-0.8 [14, [17] [18] [19] . The results of this study suggest that this low cutoff value is particularly important to use in cases involving individuals who are receiving mold-active antifungal therapy. This was illustrated best by comparison of receiver operator characteristic curves, which showed that sensitivity was highest using low cutoff values for positivity in patients not receiving antifungal therapy (figure 2B).
Case patient samples were restricted to those obtained within 14 days before or after of diagnosis, resulting in a median of 4-5 samples obtained from each patient with proven or probable IA. This frequency of sampling is consistent with current guidelines, which suggest collecting serum samples twice per week for screening. We found that the sensitivity of the assay was highest when serum samples were obtained closest to the date of diagnosis. This is not surprising, because the day of diagnosis could represent the day on which fungal burden is highest. Test results correlate with fungal burden, suggesting that it may be useful to follow up the response to antifungal therapies [20] . More studies to describe microbiological and host factors that impact the kinetics of circulating GM will be necessary before the test can be used to guide antifungal therapy.
In summary, the results of this study demonstrate that the sensitivity of the GM EIA is impaired by administration of mold-active antifungal therapy. This finding has direct implications for the use of the assay as a diagnostic aid for patients receiving mold-active antifungal therapies. A randomized trial comparing mold-active prophylaxis to GM EIA-driven "preemptive" therapy may be necessary to optimize preventive and diagnostic approaches.
